Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A415CY | ISIN: US76090R4083 | Ticker-Symbol: 24O0
NASDAQ
22.07.25 | 21:22
3,020 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
RESHAPE LIFESCIENCES INC Chart 1 Jahr
5-Tage-Chart
RESHAPE LIFESCIENCES INC 5-Tage-Chart

Aktuelle News zur RESHAPE LIFESCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiReShape Lifesciences Inc: ReShape Lifesciences to Host Inaugural Lap-Band Surgeon Summit3
MoReShape Lifesciences Inc: ReShape Lifesciences to Host Special Meeting of Stockholders on July 24, 20252
15.07.ReShape Lifesciences Inc. - 8-K, Current Report1
03.07.ReShape Lifesciences Inc. - 8-K, Current Report1
RESHAPE LIFESCIENCES Aktie jetzt für 0€ handeln
01.07.ReShape Lifesciences Inc: ReShape Lifesciences Granted U.S. Patent Related to an Intragastric Balloon System133IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8...
► Artikel lesen
27.06.ReShape Lifesciences regains Nasdaq compliance2
27.06.ReShape Lifesciences regains Nasdaq compliance after equity raises1
27.06.ReShape Lifesciences Inc: ReShape Lifesciences Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement354IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June...
► Artikel lesen
26.06.ReShape Lifesciences Intends To Reduce Workforce To Boost Operational Efficiency1
26.06.ReShape Lifesciences Inc: ReShape Lifesciences Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys168Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26,...
► Artikel lesen
25.06.ReShape Lifesciences erhält australisches Patent für Diabetes-Gerät2
25.06.ReShape Lifesciences receives Australian patent for diabetes device1
25.06.ReShape Lifesciences Inc: ReShape Lifesciences Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology1
18.06.ReShape Lifesciences Inc. - 8-K, Current Report1
12.06.ReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets859IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of...
► Artikel lesen
09.06.ReShape Lifesciences prices $2.6M public offering3
09.06.ReShape Lifesciences Inc. - 8-K, Current Report1
09.06.ReShape Lifesciences sets share price at $2.50 in public offering1
09.06.ReShape Lifesciences legt Aktienpreis bei 2,50 US-Dollar für öffentliches Angebot fest5
09.06.ReShape Lifesciences Inc: ReShape Lifesciences Announces Pricing of $2.6 Million Public Offering1
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1